Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

U.S. FDA approves Takeda's drug for post-transplant CMV infection

11/23/2021 | 05:52pm EST
FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo

(Reuters) - The U.S. Food and Drug Administration said on Tuesday it had approved Takeda Pharmaceutical Co Ltd's drug for a common type of viral infection occurring in patients after organ transplant.

The infection is caused by a type of herpes virus called cytomegalovirus (CMV) and can have a major negative impact on transplant recipients, including loss of the transplanted organ as well as death.

The FDA said it approved Takeda's drug Livtencity for use against CMV disease among patients who do not respond to available antiviral treatments.

"Cytomegalovirus infections that are resistant or do not respond to available drugs are of even greater concern," FDA official John Farley said.

"Today's approval helps meet a significant unmet medical need by providing a treatment option for this patient population."

Livtencity works by preventing the activity of an enzyme involved in virus replication. The drug will be commercially available soon, Takeda said.

CMV is one of the most common infections experienced by transplant recipients, with an estimated incidence rate of around 16%-56% in solid organ transplant recipients, the company said.

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Anil D'Silva and Krishna Chandra Eluri)


ę Reuters 2021
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
08:14aTakeda Unveils New Research to Advance Patient Care in Hematology and Oncology at 63rd ..
BU
12/03Takeda's LIVTENCITYTM (maribavir) Now Available for Certain Individuals Ages 12 Years a..
AQ
12/03Japanese Shares Close With Gains on Japan Services Data
MT
12/02Takeda Says Livtencity Commercially Available in the US for Patients 12 Years and Older
MT
12/02Takeda's LIVTENCITY™ (maribavir) Now Available for Certain Individuals Ages 12 Ye..
BU
12/02Takeda Pharmaceutical Company Limited Announces its LIVTENCITY? Now Available for Certa..
CI
12/02Takeda Pharmaceutical Buys Back Shares for $441 Million
MT
12/01GENERAL ANNOUNCEMENT : :Takeda Provides Update on Status of Acquisition of Own Shares
PU
12/01TAKEDA PHARMACEUTICAL : Provides Update on Status of Acquisition of Own Shares
PU
11/30Takeda Announces U.S. Corporate Social Responsibility (CSR) Program Aimed to Help Reduc..
BU
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Financials
Sales 2022 3 410 B 30 047 M 30 047 M
Net income 2022 220 B 1 941 M 1 941 M
Net Debt 2022 3 386 B 29 836 M 29 836 M
P/E ratio 2022 22,2x
Yield 2022 5,71%
Capitalization 4 906 B 43 194 M 43 228 M
EV / Sales 2022 2,43x
EV / Sales 2023 2,28x
Nbr of Employees 47 099
Free-Float 98,2%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 3 150,00 JPY
Average target price 4 272,86 JPY
Spread / Average Target 35,6%
EPS Revisions
Managers and Directors
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Norimasa Takeda Chief Accounting Officer & Corporate Controller
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED-16.11%42 403
JOHNSON & JOHNSON3.53%428 955
ROCHE HOLDING AG17.23%322 390
PFIZER, INC.44.09%288 950
NOVO NORDISK A/S65.08%245 091
ELI LILLY AND COMPANY45.45%223 321